Magnolia

Magnolia Neurosciences is a biotechnology company dedicated to developing a new class of neuroprotective medicines for patients suffering from neurodegenerative diseases. The company was co-founded by Accelerator Life Science Partners and the University of Texas MD Anderson Cancer Center to commercialize discoveries related to the kynurenine pathway. Their primary focus is on inhibiting kynurenine 3-monooxygenase (KMO) to prevent neuronal death and preserve neural connectivity. Magnolia's pipeline includes programs targeting chemotherapy-induced peripheral neuropathy (CIPN), glaucoma, and other neurodegenerative conditions like Alzheimer's and Parkinson's disease. By addressing the underlying mechanisms of nerve cell death, the company aims to provide disease-modifying treatments for conditions with high unmet medical needs.